Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Aug;42(8):3621-3633.
doi: 10.1007/s12325-025-03257-w. Epub 2025 Jun 5.

GLP-1 Receptor Agonists, DPP-4 Inhibitors and the Skin-Diabetes Meets Dermatology: A Brief Narrative Review

Dimitrios Pantazopoulos  1 , Evanthia Gouveri  1 , Massimo Papi  2 , Dimitrios Papazoglou  1 , Nikolaos Papanas  3
Affiliations
Review

GLP-1 Receptor Agonists, DPP-4 Inhibitors and the Skin-Diabetes Meets Dermatology: A Brief Narrative Review

Dimitrios Pantazopoulos et al. Adv Ther. 2025 Aug.

Abstract

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase 4 inhibitors (DPP-4is) are well-established agents for type 2 diabetes mellitus (T2DM) management. Ongoing research has provided data on their both beneficial and adverse effects on the skin. For instance, GLP-1RAs have exhibited therapeutic benefits in psoriasis, while DPP-4is may reduce the risk of melanoma. Moreover, both of these agents may play a pivotal role in improving wound healing. However, untoward effects, such as bullous pemphigoid, highlight the need for patient monitoring. This review summarises the beneficial and adverse effects of GLP-1RAs and DPP-4is in dermatological conditions and in systemic diseases with cutaneous manifestations.

Keywords: Adverse effects; Cutaneous disease; DPP4is; GLP-1RAs; Skin; T2DM.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of Interest: Dimitrios Pantazopoulos and Massimo Papi has no conflicts of interest. Evanthia Gouveri has attended conferences sponsored by Berlin-Chemie, Sanofi, AstraZeneca, Novo Nordisk, Lilly and Boehringer Ingelheim; received speaker honoraria by Boehringer Ingelheim and Menarini. Dimitrios Papazoglou declares associations with Menarini, Novo Nordisk, AstraZeneca, Boehringer Ingelheim and Sanofi-Aventis. Nikolaos Papanas has been an advisory board member of AstraZeneca, Bayer, Boehringer Ingelheim, Menarini, MSD, Novo Nordisk, Pfizer, Takeda and TrigoCare International; has participated in sponsored studies by AstraZeneca, Eli Lilly, GSK, MSD, Novo Nordisk, Novartis and Sanofi-Aventis; has received honoraria as a speaker for AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Elpen, Menarini, MSD, Mylan, Novo Nordisk, Pfizer, Sanofi-Aventis and Vianex; and has attended conferences sponsored by TrigoCare International, Bayer, Eli Lilly, Galenica, Novo Nordisk, Pfizer and Sanofi-Aventis. Ethical Approval: This review is based on previously conducted studies and meta-analyses and does not contain any new studies with human participants or animals performed by any of the authors.

Similar articles

See all similar articles

References

    1. Yazbeck R, Howarth GS, Abbott CA. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol Sci. 2009;30:600–7. - PubMed
    1. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia. 2022;65:1925–66. - PMC - PubMed
    1. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes—state-of-the-art. Mol Metab. 2021;46:101102. - PMC - PubMed
    1. Pathak R, Bridgeman MB. Dipeptidyl peptidase-4 (DPP-4) inhibitors in the management of diabetes. P T. 2010;35:509–13. - PMC - PubMed
    1. Tella SH, Rendell MS. DPP-4 inhibitors: focus on safety. Expert Opin Drug Saf. 2015;14:127–40. - PubMed

MeSH terms

Substances

LinkOut - more resources